

Alberto Mussetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4353189/publications.pdf>

Version: 2024-02-01

74
papers

1,231
citations

430874

18
h-index

395702

33
g-index

76
all docs

76
docs citations

76
times ranked

2018
citing authors

#	ARTICLE	IF	CITATIONS
1	Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 440-443.	0.2	4
2	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
3	A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. <i>Bone Marrow Transplantation</i> , 2022, 57, 176-182.	2.4	1
4	Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with <i>Pseudomonas aeruginosa</i> Pneumonia. <i>Microorganisms</i> , 2022, 10, 733.	3.6	6
5	COVID19 in hematological patients and telemedicine: lessons learned across Europe and the US. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 295-301.	3.1	2
6	Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. <i>EJHaem</i> , 2021, 2, 112-114.	1.0	1
7	Old and new generation proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021, 62, 193-206.	0.8	6
8	A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 116.	1.6	23
9	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27
10	Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot Study. <i>JMIR Formative Research</i> , 2021, 5, e26121.	1.4	8
11	The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting. <i>Cancer Reports</i> , 2021, 4, e1358.	1.4	6
12	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 3214-3223.	2.8	73
13	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	4.6	43
14	Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. <i>Kidney Medicine</i> , 2021, 3, 665-668.	2.0	10
15	Is Post-Transplant Cyclophosphamide the New Methotrexate?. <i>Journal of Clinical Medicine</i> , 2021, 10, 3548.	2.4	11
16	Synchronizing the use of allogeneic hematopoietic cell transplantation in checkpoint blockade therapy for Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 809-818.	2.2	1
17	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
18	Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2021, 5, 3418-3426.	5.2	17

#	ARTICLE	IF	CITATIONS
19	Allogeneic STEM Cell Transplantation in 45 Patients with Myelodysplastic Syndrome: Single-Center Analysis. <i>Blood</i> , 2021, 138, 4913-4913.	1.4	0
20	Real-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study. <i>Blood</i> , 2021, 138, 3850-3850.	1.4	0
21	Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study. <i>Blood</i> , 2021, 138, 174-174.	1.4	3
22	Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. <i>Blood</i> , 2021, 138, 1742-1742.	1.4	1
23	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	1.4	4
24	Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin's lymphoma with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 483-484.	2.4	1
25	Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure. <i>Journal of Clinical Medicine</i> , 2020, 9, 3437.	2.4	3
26	Handling the COVID-19 pandemic in the oncological setting. <i>Lancet Haematology</i> , 2020, 7, e365-e366.	4.6	12
27	What's behind chronic graft versus host disease incidence curves?. <i>Lancet Haematology</i> , 2020, 7, e83-e84.	4.6	1
28	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <i>Annals of Hematology</i> , 2020, 99, 867-875.	1.8	8
29	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19
30	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
31	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	33
32	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-21.	1.4	4
33	Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
34	Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
35	Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. <i>Leukemia and Lymphoma</i> , 2019, 60, 477-482.	1.3	7
36	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58

#	ARTICLE	IF	CITATIONS
37	PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression. <i>Annals of Hematology</i> , 2019, 98, 1713-1720.	1.8	15
38	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1237-1244.	2.4	5
39	Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323.	1.4	2
40	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61
41	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1522-1531.	2.4	22
42	CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S297.	2.0	0
43	Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. <i>Annals of Hematology</i> , 2018, 97, 1301-1315.	1.8	6
44	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. <i>Expert Review of Hematology</i> , 2017, 10, 479-492.	2.2	34
45	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
46	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1549-1554.	2.0	25
47	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	3.1	4
48	Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. <i>Cancer</i> , 2017, 123, 3701-3708.	4.1	12
49	Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. <i>Bone Marrow Transplantation</i> , 2017, 52, 1602-1608.	2.4	13
50	ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS). <i>Hematological Oncology</i> , 2017, 35, 169-190.	1.7	0
51	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	1.0	40
52	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
53	Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or mismatched donors. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 347-358.	0.8	3
54	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 58-66.	2.4	36

#	ARTICLE	IF	CITATIONS
55	Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis. <i>Blood</i> , 2016, 128, 3475-3475.	1.4	1
56	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). <i>Blood</i> , 2016, 128, 3473-3473.	1.4	0
57	Role of Cell Source and Graft Composition in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016, 128, 4664-4664.	1.4	0
58	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€“Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
59	Bendamustine in relapsed/refractory multiple myeloma: the â€œreal-lifeâ€•side of the moon. <i>Leukemia and Lymphoma</i> , 2015, 56, 1510-1513.	1.3	7
60	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
61	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. <i>Bone Marrow Transplantation</i> , 2015, 50, 1293-1298.	2.4	15
62	Highly Prolonged Overall Survival Following Reduced Intensity Allogeneic Stem Cell Transplantation for Multiple Myeloma in the New Drugs Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e281-e282.	0.4	0
63	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1969-1974.	1.3	3
64	Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. <i>Blood Reviews</i> , 2015, 29, 143-152.	5.7	8
65	Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 194-194.	1.4	1
66	Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI). <i>Blood</i> , 2015, 126, 2697-2697.	1.4	6
67	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. <i>Leukemia and Lymphoma</i> , 2014, 55, 2032-2037.	1.3	22
68	Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective Analysis in the Rituximab Era. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S75-S76.	2.0	0
69	Alternate Clonal Dominance in Richter Transformation Presenting as Extranodal Diffuse Large B-Cell Lymphoma and Synchronous Classic Hodgkin Lymphoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 227-232.	0.7	6
70	Effective treatment of pomalidomide in central nervous system myelomatosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 864-866.	1.3	51
71	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24
72	Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.. <i>Blood</i> , 2012, 120, 2971-2971.	1.4	0

#	ARTICLE	IF	CITATIONS
73	The Use of High Resolution Melting (HRM) Analysis for Molecular Gene Defects of Type 3 Von Willebrand Disease: Studies of An Italian Cohort of 10 Patients.. Blood, 2009, 114, 3498-3498.	1.4	0
74	Post thawing viable CD34+â€™%Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	2